Lanadelumab is under clinical development by Takeda Pharmaceutical and currently in Phase III for Angioedema. According to GlobalData, Phase III drugs for Angioedema have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Lanadelumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lanadelumab overview
Lanadelumab (Takhzyro) recombinant, fully human, monoclonal antibody (IgG1/ κ -light chain) produced in Chinese Hamster Ovary (CHO) cells. It is formulated as injectable solution for subcutaneous route of administration. Takhzyro is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients of 12 years and older.
See Also:
Lanadelumab (DX-2930, SHP643, TAK-743) is under development for the prophylactic treatment of Coronavirus disease 2019 (COVID-19), plasma kallikrein (bradykinin) mediated Hereditary Angioedema (HAE). The therapeutic candidate is administered as subcutaneous and intravenous injection. It is a fully human monoclonal antibody acts by targeting plasma kallikrein. It was also under development for diabetic macular edema and Coronavirus disease 2019 (COVID-19) pneumonia, factor XII-associated cold autoinflammatory syndrome (FACAS).
Takeda Pharmaceutical overview
Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company, which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of drugs. It provides treatment for inflammatory bowel disease, acid-related diseases, motility disorders and liver diseases; hemophilia and hereditary bleeding disorders; primary immunodeficiency and multifocal motor neuropathy; major depressive disorder and attention-deficit hyperactivity disorder; and its cancer treatment encompasses multiple myeloma, mantle cell lymphoma, non-small cell lung cancer and chronic myeloid leukemia. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.
For a complete picture of Lanadelumab’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
